Back to Search
Start Over
Extended-spectrum beta-lactamases. An overview.
- Source :
-
Postgraduate medicine [Postgrad Med] 2001 Feb; Vol. 109 (2 Suppl), pp. 32-8. - Publication Year :
- 2001
-
Abstract
- The emergence of extended-spectrum beta-lactamase (ESBL)- producing Klebsiella pneumoniae and other ESBL-producing Enterobacteriaceae is an increasing problem and presents a dilemma for clinicians. The problem is not only detection of this resistance in the microbiology laboratory, but also a therapeutic dilemma due to multiple drug resistance to extended-spectrum beta-lactams and other agents, including fluoroquinolones, trimethoprim-sulfamethoxazole, and gentamicin. Currently, imipenem appears to be the drug of choice for serious infections due to these isolates, based on accumulating clinical experience. Because options for therapy are limited, control and prevention measures are particularly important. These should include not only traditional infection control measures such as contact precautions, but also antibiotic utilization measures, such as widespread empiric use of ceftazidime.
- Subjects :
- Aminoglycosides pharmacology
Aminoglycosides therapeutic use
Anti-Bacterial Agents pharmacology
Anti-Bacterial Agents therapeutic use
Cephamycins pharmacology
Cephamycins therapeutic use
Enterobacteriaceae drug effects
Enterobacteriaceae Infections drug therapy
Fluoroquinolones pharmacology
Fluoroquinolones therapeutic use
Humans
Imipenem therapeutic use
Risk Factors
beta-Lactam Resistance drug effects
Drug Resistance, Multiple, Bacterial drug effects
Enterobacteriaceae enzymology
Enterobacteriaceae Infections microbiology
beta-Lactamases biosynthesis
Subjects
Details
- Language :
- English
- ISSN :
- 1941-9260
- Volume :
- 109
- Issue :
- 2 Suppl
- Database :
- MEDLINE
- Journal :
- Postgraduate medicine
- Publication Type :
- Academic Journal
- Accession number :
- 19667555
- Full Text :
- https://doi.org/10.3810/pgm.02.2001.suppl12.63